The trial that followed was a masterclass in scientific caution and ethics.
In the spring of 2023, Dr. Elena Márquez, a virologist at the Nordic Institute of Viral Therapeutics, received an urgent alert. A novel strain of influenza—dubbed H17N9 “Phoenix”—had emerged from a wetland in Southeast Asia. Unlike seasonal flu, Phoenix had a mortality rate of nearly 25 percent in healthy adults. The World Health Organization declared a Public Health Emergency of International Concern. anti virus trial
But the trial also revealed a serious flaw. In two patients with pre-existing kidney disease, the drug accumulated to toxic levels, causing acute renal failure. Both recovered after dialysis, but the data were clear: AVI-7 could not be given without prior kidney function screening. The drug’s label would need a bolded warning. The trial that followed was a masterclass in
With regulatory approval, 40 healthy volunteers received ascending doses of AVI-7 at a hospital in Oslo. The goal: find side effects. Most reported mild nausea. Two developed temporary liver enzyme elevations, setting a maximum safe dose. No one died. No one got sick from the virus because they were never exposed to it. But the trial also revealed a serious flaw